Overview

Combination of the Immune Modulator Dimethyl Fumarate With Alteplase in Acute Ischemic Stroke

Status:
Not yet recruiting
Trial end date:
2021-12-31
Target enrollment:
0
Participant gender:
All
Summary
The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in combination with alteplase in patients with Acute Ischemic Stroke.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Xuanwu Hospital, Beijing
Treatments:
Dimethyl Fumarate
Criteria
Inclusion Criteria:

1.18-80 years old 2. NIHSS score>5 3. First stroke, MRI shows anterior cerebral artery and
middle cerebral artery obstruction 4. Patients who meet Alteplase thrombolytic therapy
within 4.5h

Exclusion Criteria:

1. Alteplase contraindications

2. Other diseases of the central nervous system

3. There has been a neurological disability in the past (mRS score>2)

4. Difficulty swallowing

5. Arrhythmia, atrioventricular block

6. Use of anti-tumor drugs, other immunosuppressive and immunomodulatory drugs

7. Macular edema

8. Magnetic resonance angiography(MRA) shows obstruction of internal carotid artery and
vertebrobasilar artery

9. Hemorrhagic stroke

10. Patients who are known to have hypersensitivity to dimethyl fumarate or any excipients
of this product

11. Pregnant and lactating women